Interferons, immunity and cancer immunoediting
The DOI matches its Crossref record; 118 of the 119 references it cites were found in a registry or an index.
Abstract
A clear picture of the dynamic relationship between the host immune system and cancer is emerging as the cells and molecules that participate in naturally occurring antitumour immune responses are being identified. The interferons (IFNs) - that is, the type I IFNs (IFNalpha and IFNbeta) and type II IFN (IFNgamma) - have emerged as central coordinators of tumour-immune-system interactions. Indeed, the decade-old finding that IFNgamma has a pivotal role in promoting antitumour responses became the focus for a renewed interest in the largely abandoned concept of cancer immunosurveillance. More recently, type I IFNs have been found to have distinct functions in this process. In this Review, we discuss the roles of the IFNs, not only in cancer immunosurveillance but also in the broader process of cancer immunoediting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a cytokine which promotes increased tumour immunogenicity and often used to assess T-cell activation31”
From Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis (2016) · cites this paper as [31]
Citations
Cites
1 retracted
Urisman, A., Molinaro, R. J., Fischer, N., Plummer, S. J., Casey, G., Klein, E. A., Malathi, K., Magi-Galluzzi, C., Tubbs, R. R., Ganem, D., et al. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020025 · Cited by 577 · cited 1×
“However, it remains unclear whether the tumour-suppressor functions of RNaseL depend on IFN”
BackgroundRetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · cited 1×
“Using a combination of histological and gene-expression analyses, Galon et al”
MethodCancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Self-citationCancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249 · cited 1×
“These pathways coordinately defend cells from the oncogenic and/or genotoxic stimuli that can lead to malignant transformatio”
BackgroundHOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932 · cited 1×
“Detailed reviews of IFN biology have been published elsewher”
BackgroundSelf-citationMechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Self-citationThe Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Self-citationIFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Self-citation
Research works printed but not linked: 1
- Yang, J., Murphy, T. L., Ouyang, W. & Murphy, K. M. Induction of interferon-γ production in TH1 CD4+ T cells: evidence for two distinct pathways for promoter activation. Eur. J. Immunol. 29, 548–555 (1999). · DOI · Paper page
Cited by
Items 901–1,000 of 1,002
Schirrmacher, V. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1033 · Cited by 19
Parajuli, N., Müller‐Holzner, E., Böck, G., Werner, E. R., Villunger, A., & Doppler, W. (2009) · International Journal of Cancer · doi:10.1002/ijc.24805 · Cited by 20
“, by macrophage activation, T-helper cell differentiation and immunoglobulin class switch.(1,38) Cytokines including IFN-c also appear to be critically involved in the development of immune suppression mediated by the tumor and contribute to the establishment of myeloid-derived suppressor cells and the induction of an…”
BackgroundIntact interferon signaling in peripheral blood leukocytes of high-grade osteosarcoma patients
Buddingh, E. P., Ruslan, S. E. N., Berghuis, D., Gelderblom, H. A. J., Anninga, J., Hogendoorn, P. C. W., Egeler, R. M., Schilham, M. W., & Lankester, A. C. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1232-6 · Cited by 19
“suffering from breast cancer, melanoma, and gastrointestinal cancer [15–18].”
BackgroundRazaghi, A., Villacrés, C., Jung, V., Mashkour, N., Butler, M., Owens, L., & Heimann, K. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.08.014 · Cited by 19
Integrating Costimulatory Agonists to Optimize Immune-Based Cancer Therapies
Pardee, A. D., Wesa, A. K., & Storkus, W. J. (2009) · Immunotherapy · doi:10.2217/1750743x.1.2.249 · Cited by 20
The Role of Tyk2 in Regulation of Breast Cancer Growth
Zhang, Q., Sturgill, J., Kmieciak, M., Szczepanek, K., Derecka, M., Koebel, C. M., Graham, L., Dai, Y., Chen, S., Grant, S., et al. (2011) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2011.0023 · Cited by 22
Self-citationTakahashi, Y., Kaneda, H., Takasuka, N., Hattori, K., Nishikawa, M., & Takakura, Y. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00850.x · Cited by 20
Yan, J., Zhu, J., Li, X., Yang, R., Xiao, W., Huang, C., & Zheng, C. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154968 · Cited by 21
He, W., Lv, W., Liu, L., Gong, Y., Song, K., Xu, J., Zhao, W., Li, S., Min, Z., Chen, Q., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c13470 · Cited by 18
Carluccio, S., Delbue, S., Signorini, L., Setola, E., Bagliani, A., Valle, A. D., Galli, A., Ferrante, P., & Bregni, M. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.24886 · Cited by 18
“IFN-g is one the main cytokines able to induce opposing effects on tumors, and its role in promoting anti-tumor immunity has been extensively reviewed by Brassard et al., 2002; Dunn et al., 2006 and Ikeda et al., 2002.”
Diener, K. R., Woods, A. E., Manavis, J., Brown, M. P., & Hayball, J. D. (2008) · Laboratory Investigation · doi:10.1038/labinvest.2008.123 · Cited by 18
“Here, by crossing dnTGFRII mice with TRAMP mice to generate mice in which prostate cancers developed in the presence of T cells insensitive to the effects of TGFb secretion, we provide data in further support of other genetic evidence for T-cell-mediated surveillance of malignant change.(46) The mechanism underlying o…”
RNA interference with EAG1 enhances interferon gamma injury to glioma cells in vitro.
Cunha, L. C., Bel, E. D., Pardo, L. A., Stühmer, W., & Titze‐de‐Almeida, R. (2013) · PubMed · Cited by 20
ILT4 in Colorectal Cancer Cells Induces Suppressive T Cell Contexture and Disease Progression
Yang, Z., Gao, A., Shi, W., Wang, J., Zhang, X., Xu, Z., Xu, T., Zheng, Y., Sun, Y., & Yang, F. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s290348 · Cited by 18
Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma
Reina-Ortiz, C., Giraldos, D., Azaceta, G., Palomera, L., Marzo, I., Naval, J., Villalba, M., & Anel, A. (2022) · Cells · doi:10.3390/cells11030392 · Cited by 19
“This pleiotropic cytokine is able to induce apoptosis in some circumstances, but also to inhibit angiogenesis and contribute to the activation of both innate and adaptive immune anti-tumor responses [31].”
BackgroundSystemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
Escors, D., Bocanegra, A., Chocarro, L., Blanco, E., Piñeiro‐Hermida, S., Garnica, M., Fernández, L., Vera, R., Arasanz, H., & Kochan, G. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113241 · Cited by 19
Sun, L., Li, W., Lin, Z., Duan, X., Xing, E., Jiang, M., Yang, N., Qi, H.-H., Sun, Y. N., Li, M., et al. (2015) · Cell and Tissue Research · doi:10.1007/s00441-014-2083-6 · Cited by 18
A multi-functional role of interferon regulatory factor-8 in solid tumor and myeloid cell biology
Abrams, S. I. (2009) · Immunologic Research · doi:10.1007/s12026-009-8125-6 · Cited by 18
“These findings were, therefore, consistent with the ‘‘cancer immunoediting’’ concept [38, 39] and extended this notion further to implicate the Fas/FasL system as a potentially important element of the selection process.”
BackgroundResultSchmiedel, B. J., Werner, A., Steinbacher, J., Nuebling, T., Buechele, C., Große‐Hovest, L., & Salih, H. R. (2013) · Molecular Therapy · doi:10.1038/mt.2013.11 · Cited by 18
Host Immunosurveillance Controls Tumor Growth via IFN Regulatory Factor-8–Dependent Mechanisms
Greeneltch, K. M., Schneider, M., Steinberg, S. M., Liewehr, D. J., Stewart, T. J., Liu, K., & Abrams, S. I. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1228 · Cited by 19
“The IFN-g pathway plays an important role in host-tumor immunosurveillance (29, 30 ) and proinflammatory antitumor responses, in part, by sensitizing tumor cells to apoptosis (11, 19).”
BackgroundMahnke, Y. D., Devêvre, E., Baumgaertner, P., Matter, M., Rufer, N., Romero, P. J., & Speiser, D. E. (2012) · OncoImmunology · doi:10.4161/onci.19856 · Cited by 18
Zhang, H., Zhu, Z., Zhang, F., & Meadows, G. G. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-09614-8_18 · Cited by 20
Zhang, L., Reddy, N., & Koyyalamudi, S. R. (2014) · Studies in natural products chemistry · doi:10.1016/b978-0-444-63281-4.00005-7 · Cited by 20
Autologous white blood cell transfusion: Toward a younger immunity
Charron, D. J. (2007) · Human Immunology · doi:10.1016/j.humimm.2007.07.004 · Cited by 20
Overes, I. M., Levenga, T. H., Vos, J. C. M., van Horssen-Zoetbrood, A., van der Voort, R., de Mulder, P. H., de Witte, T. M., & Dolstra, H. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0569-3 · Cited by 18
“InXammatory cytokines are known to play a role in antitumor immunity [9].”
BackgroundColeman, D. J., Garcia, G., Hyter, S., Jang, H. S., Chagani, S., Liang, X., Larue, L., Ganguli-Indra, G., & Indra, A. K. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004321 · Cited by 17
“First, we confirmed that both cell types express the primary receptor for IFN-c (IFNGR1) pre- and 24 h post-UVR using Western Blot (Figure 3D).”
BackgroundInfluentialGao, P., Li, X., Duan, Z., Wang, Y., Li, Y., Wang, J., Luo, K., & Chen, J. (2025) · MedComm · doi:10.1002/mco2.70274 · Cited by 21
Yi, J., Lin, P., Li, Q., Zhang, A., & Kong, X. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2023.08.010 · Cited by 17
Su, H., Chen, Y., & Wang, W.-K. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e38230 · Cited by 17
Liang, H. L., Deng, L., Burnette, B., Weichselbaum, R. R., & Fu, Y. (2013) · OncoImmunology · doi:10.4161/onci.25668 · Cited by 17
Hayashi, T., Ding, Q., Kuwahata, T., Maeda, K., Miyazaki, Y., Matsubara, S., Obara, T., Natsugoe, S., & Takao, S. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02235.x · Cited by 17
Grenz, S., Naschberger, E., Merkel, S., Britzen‐Laurent, N., Schaal, U., Konrad, A., Aigner, M., Rau, T. T., Hartmann, A., Croner, R. S., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.08.025 · Cited by 19
“Interferons are inducible cytokines with antiviral and cell growth regulatory effects as well as anti-tumor activities and emerge as central coordinators of the tumor-immune system interactions.(12) The type II interferon, IFN-g, targets the maturation, differentiation, and activation of immune cells and leads to an i…”
BackgroundEndogenous galectin-3 expression levels modulate immune responses in galectin-3 transgenic mice
Chaudhari, A. D., Gude, R. P., Kalraiya, R. D., & Chiplunkar, S. V. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.09.015 · Cited by 18
Gasparri, M. L., Ruscito, I., Taghavi, K., Farooqi, A. A., Papadia, A., Focaccetti, C., Barnaba, V., Panici, P. B., & Mueller, M. D. (2017) · Springer eBooks · doi:10.1007/978-3-319-53082-6_9 · Cited by 26
A Novel Pyroptosis-related Prognostic Model for Hepatocellular Carcinoma
Wu, Q., Jiang, S., Cheng, T., Xu, M., & Lu, B. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.770301 · Cited by 18
“IFNs have been identified as pivotal factors in coordinating the interactions between tumors and the immune system (Dunn et al., 2006).”
BackgroundWang, Y., Zhang, G., Meng, Q., Huang, S., Guo, P., Leng, Q., Sun, L., Liu, G., Huang, X., & Liu, J. (2022) · Nature Communications · doi:10.1038/s41467-022-29120-y · Cited by 18
Rojas‐Domínguez, A., Arroyo-Duarte, R., Rincón-Vieyra, F., & Alvarado, M. (2022) · BMC Bioinformatics · doi:10.1186/s12859-022-04731-w · Cited by 17
“By the beginning of the twenty-first century, several important discoveries had guided the evolution of the immunosurveillance hypothesis into the concept of cancer immunoediting (CI); a brief review of that evolution is found in [1, 2].”
BackgroundTang, B., Wang, Y., Zhu, J., Song, J., Fang, S., Weng, Q., Yang, Y., Tu, J., Zhao, Z., Chen, M., et al. (2023) · Biological Procedures Online · doi:10.1186/s12575-023-00199-x · Cited by 17
Fenaux, J., Fang, X., Huang, Y.-M., Melero, C., Bonnans, C., Lowe, E. L., Palumbo, T., Lay, C., Yi, Z., Zhou, A., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2217737 · Cited by 19
Pato, A., Eisenberg, G., Machlenkin, A., Margalit, A., Cafri, G., Frankenburg, S., Merims, S., Peretz, T., Lotem, M., & Gross, G. (2015) · Clinical & Experimental Immunology · doi:10.1111/cei.12688 · Cited by 17
Lion, E., Smits, E., Berneman, Z. N., & Tendeloo, V. F. V. (2009) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.08.014 · Cited by 17
Simultaneous TLR2 inhibition and TLR9 activation synergistically suppress tumor metastasis in mice
Yan, J., Hua, F., Liu, H.-Z., Yang, H.-Z., & Hu, Z. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.193 · Cited by 17
Gerbitz, A., Sukumar, M., Helm, F., Wilke, A., Friese, C., Fahrenwaldt, C., Lehmann, F., Loddenkemper, C., Kammertoens, T., Mautner, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034552 · Cited by 19
“In about 25% of the cases, lymphomas grew out with delayed kinetics, were GFPnegative and had upregulated MHC class I and class II expression, representing cells that had either been selected for loss of antigen expression in vivo [29], or more likely, for cells that had not been retrovirally transduced.”
BackgroundScarpa, M., Cardin, R., Bortolami, M., Kotsafti, A., Scarpa, M. C., Pozza, A., Maran, G., Piciocchi, M., Ruffolo, C., Renata D'Incà, et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.05.015 · Cited by 17
“Cancer immunoediting could be a process leading to neoplastic cell destruction (immunosurveillance) mediated by T-cells, macrophages, and natural killer cells.(3) Activation of T-cells requires engagement of T-cell receptors with antigen-specific, major histocompatibility complex restricted receptors in the presence o…”
BackgroundAbbas, A. K., Lichtman, A. H., Pillai, S. S., & Baker, D. L. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-3123-9.50026-7 · Cited by 17
Ecrg4 contributes to the anti-glioma immunosurveillance through type-I interferon signaling
Moriguchi, T., Kaneumi, S., Takeda, S., Enomoto, K., Mishra, S. K., Miki, T., Koshimizu, U., Kitamura, H., & Kondo, T. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1242547 · Cited by 19
“11 pro-inflammatory factors, il6, il12 p40 subunit and tnfα, and a type-I IFN ifnβ, which activates critical components of the innate and adaptive immune systems underlying cancer immunosurveillance (18,19), in the Ecrg4 fragment-treated microglia (Fig.”
BackgroundThe evolving understanding of immunoediting and the clinical impact of immune escape
McCoach, C. E., & Bivona, T. G. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.03.60 · Cited by 21
“With additional advances in our understanding of the multifaceted relationship between tumor cells, the tumor microenvironment and the immune system, immunosurveillance is now considered to be one component of immunoediting (4-6).”
BackgroundShi, Y., Wang, Y., Yang, R., Zhang, W., Zhang, Y., Feng, K., Lv, Q., Niu, K., Chen, J., Li, L., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1090324 · Cited by 16
“Moreover, the expression of Type_II_IFN_Response in the high-risk group was significantly higher than those in the low-risk group, which was identified as a key factor in coordinating the interaction between tumors and the immune system (37).”
BackgroundMultiomics characteristics and immunotherapeutic potential of EZH2 in pan-cancer
Luo, L., Wang, Z., Hu, T., Feng, Z., Zeng, Q., Shu, X., Wu, A., Huang, P., Cao, Y., Tu, Y., et al. (2023) · Bioscience Reports · doi:10.1042/bsr20222230 · Cited by 16
Tumor-Homing Antibody-Cytokine Fusions for Cancer Therapy
Prodi, E., Neri, D., & Luca, R. D. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s480787 · Cited by 16
Calabrò, M. L., Gasperini, P., Gangi, I. M. D., Indraccolo, S., Barbierato, M., Amadori, A., & Chieco‐Bianchi, L. (2009) · Blood · doi:10.1182/blood-2008-09-180307 · Cited by 16
Ding, X., Zhao, T., Lee, C., Yan, C., & Du, H. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.10.007 · Cited by 17
Intra-tumoral heterogeneity and immune responses predicts prognosis of gastric cancer
Feng, W., Wang, Y., Chen, S., & Zhu, X. (2020) · Aging · doi:10.18632/aging.202238 · Cited by 16
“Although IFN- γ has not yet been approved for medical treatment, it has improved the survival of bladder carcinoma in clinical trial [18].”
BackgroundIFN ‐α/β‐mediated NK2R expression is related to the malignancy of colon cancer cells
Xiang, H., Toyoshima, Y., Shen, W., Wang, X., Okada, N., Kii, S., Sugiyama, K., Nagato, T., Kobayashi, H., Ikeo, K., et al. (2022) · Cancer Science · doi:10.1111/cas.15397 · Cited by 17
Novel Insights into the Role of the Antioxidants in Prostate Pathology
Rago, V., & Agostino, S. D. (2023) · Antioxidants · doi:10.3390/antiox12020289 · Cited by 17
Ou, H. D., May, A. P., & O’Shea, C. C. (2010) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.88 · Cited by 19
STAT1 Represses Skp2 Gene Transcription to Promote p27Kip1 Stabilization in Ras-Transformed Cells
Wang, S., Raven, J. F., & Koromilas, A. E. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0027 · Cited by 16
“STAT1 exhibits tumor-suppressor functions through its ability to promote the immunosurveillance of tumors in mouse models (17).”
BackgroundValeta-Magara, A., Hatami, R., Axelrod, D., Roses, D. F., Guth, A. A., Formenti, S. C., & Schneider, R. J. (2015) · SpringerPlus · doi:10.1186/s40064-015-1260-8 · Cited by 21
Carinelli, S., Xufré, C., Martí, M., & Pividori, M. I. (2018) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2018.05.030 · Cited by 16
In situ administration of cytokine combinations induces tumor regression in mice
Zhang, J., Jiang, H., & Zhang, H. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.050 · Cited by 16
“The therapeutic effects of interferons, which are considered important in cancer immunoediting, have been evaluated inmany clinic trials [14].”
BackgroundType I Interferons as Joint Regulators of Tumor Growth and Obesity
Gessani, S., & Belardelli, F. (2021) · Cancers · doi:10.3390/cancers13020196 · Cited by 16
Li, B. E., Li, G. Y., Cai, W., Zhu, Q., Seruggia, D., Fujiwara, Y., Vakoc, C. R., & Orkin, S. H. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009455 · Cited by 16
“45 IFNs display a range of antitumor activities, including induction of apoptosis, inhibition of angiogenesis and proliferation, cell terminal differentiation, and immune regulation.”
Serum levels of type I interferon (IFN-I) is associated with the severity of COVID-19
Sun, Y., Wang, G., Wang, R., Ren, L., Yuan, Z., Liu, Y., Wu, Y., Chen, R., Chen, Y., & Diao, B. (2023) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001694 · Cited by 15
Li, W.-K., Zhuang, Y., Shao, S., Trivedi, P., Zheng, B., Huang, G., He, Z., & Zhang, X. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13163 · Cited by 16
Inatsuka, C., Yang, Y., Gad, E. A., Rastetter, L., Disis, M. L., & Lu, H. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1436-4 · Cited by 16
“IFN-c plays an important role in promoting anti-tumor immune response and controlling tumor growth [28].”
Ilkovitch, D., Handel-Fernandez, M. E., Herbert, L. M., & Lopez, D. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5651 · Cited by 15
“IFN-g is known to play a great role in the cancerimmunoediting process and can serve as a bridge between innate and adaptive immunity (37).”
BackgroundHedreul, M. T., Möller, S., Stridh, P., Gupta, Y., Gillett, A., Beyeen, A. D., Öckinger, J., Flytzani, S., Diez, M., Olsson, T. P., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt343 · Cited by 16
Strannegård, Ö. O., & Thorén, F. B. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1091147 · Cited by 15
“decades of intense debate, it is now generally accepted that the immune system has a role in cancer,(2) and that it may act as a double-edged sword on a tumor.(3) Thus, on the one hand, cyto-”
BackgroundLiu, Z., Zheng, F., Mao, Y., Ye, L., Bian, J., Lai, D., Ye, Y., & Dai, Y. (2017) · Oncology Letters · doi:10.3892/ol.2017.6080 · Cited by 15
“IFN-γ may be involved in the regulation of PD-L1 via certain signaling pathways, including the Janus kinase (JAK)/signal transducer and activator of transcription 1 (STAT1)/interferon regulatory factor-1 (IRF-1); phosphoinositide-3 kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR)/S6 K and methyl ethyl ketone (…”
BackgroundYi, L., Chen, L., Guo, X., Lu, T., Wang, H., Ji, X., Zhang, J., Ren, Y., Pan, P., Kinghorn, A. D., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01509 · Cited by 16
“However, exogenously delivered IFN-γ has been studied in several clinical trials with little success due to its toxic effects (10).”
BackgroundYang, Q., Huang, G., Li, L., Li, E., & Xu, L. (2021) · Journal of Immunology Research · doi:10.1155/2021/5964752 · Cited by 17
“Recently, IFNs, especially IFN-γ, have been reported to have important roles in tumor immunotherapy [54].”
BackgroundAsterholm, I. W., Kim-Muller, J. Y., Rutkowski, J. M., Crewe, C., Tao, C., & Scherer, P. E. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.04.017 · Cited by 17
“Th1-type immune responses, characterized by an increased IFNg production, typically promote tumor rejection; however less is known regarding the contribution of Th2 and Th17 responses in tumor progression.(42) Although the colonic expression of IFNg is not significantly different between genotypes in the AOM-DSS colon…”
BackgroundMarasca, F., Gasparotto, E., Polimeni, B., Vadalà, R., Ranzani, V., & Bodega, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093201 · Cited by 15
van Kesteren, P. C. E., Beems, R. B., Luijten, M., Robinson, J. F., de Vries, A., & STEEG, H. V. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp013 · Cited by 15
The curious case of type I interferon signaling in cancer
Chhipa, A. S., Boscaro, V., Gallicchio, M., & Patel, S. S. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189204 · Cited by 15
Immunocombination Therapy for High-Risk Neuroblastoma
Kroesen, M., Lindau, D., Hoogerbrugge, P. M., & Adema, G. J. (2012) · Immunotherapy · doi:10.2217/imt.11.169 · Cited by 14
Scutti, J. B. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4283 · Cited by 14
“They also contributed in describing immunoediting and how cancer cells became less immunogenic than the starting population (15-19).”
Grigorieva, J., Asmellash, S. G., Oliveira, C., Röder, H., Net, L., & Roder, J. (2019) · Clinical mass spectrometry · doi:10.1016/j.clinms.2019.09.001 · Cited by 16
The role of cytokines in the pathogenesis of malignant neoplasms
Львовна, Р. В., Adamova, G. V., & Oslina, D. S. (2023) · Сибирский научный медицинский журнал · doi:10.18699/ssmj20230202 · Cited by 14
Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology
Foster, J., Alonso, M. M., Sayour, E. J., Davidson, T. B., Persson, M. L., Dun, M. D., Kline, C., Mueller, S., Vitanza, N. A., & van der Lugt, J. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100909 · Cited by 14
Human leukocyte antigen (HLA)‐G gene polymorphism in patients with non‐small cell lung cancer
Kowal, A., Wiśniewski, A., Kuśnierczyk, P., & Jankowska, R. (2015) · Thoracic Cancer · doi:10.1111/1759-7714.12232 · Cited by 14
Multiple kinases in the interferon-γ response
Watling, D., do Carmo, C. R., Kerr, I. M., & Costa‐Pereira, A. P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710814105 · Cited by 14
“I (IFNs) are essential to the control of infection and the immune response, and manifest tumor suppressor function(s) (1, 2).”
BackgroundIFNα signaling through PKC-θ is essential for antitumor NK cell function
Comet, N. R., Aguiló, J. I., Rathore, M. G., Catalán, E., Garaude, J., Uzé, G., Naval, J., Pardo, J., Villalba, M., & Anel, A. (2014) · OncoImmunology · doi:10.4161/21624011.2014.948705 · Cited by 14
Avidan, A., Perlmutter, M., Tal, S., Oraki, O., Kapp, T., Krelin, Y., Elkabets, M., Dotan, S., Apte, R. N., & Lichtenstein, R. G. (2009) · Glycoconjugate Journal · doi:10.1007/s10719-009-9238-9 · Cited by 14
“Recently, processes of immunoediting, in which immunity controls and shapes tumor cell immunogenicity, were described [7, 8].”
BackgroundScarpa, M., Bortolami, M., Cecchetto, A., Faggian, D., Kotsafti, A., Ruffolo, C., Navaglia, F., Pozza, A., Renata D'Incà, Plebani, M., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.10.010 · Cited by 14
Ujvári, D., Nagy, N., Madapura, H. S., Kallas, T., Kröhnke, M. C. L., Stenke, L., Klein, E., & Salamon, D. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.03.010 · Cited by 14
Novel identification of STAT1 as a crucial mediator of ETV6-NTRK3-induced tumorigenesis
Park, J., Kim, J., Park, B.-R., Yang, K., Sun, E. J., Tognon, C. E., Sorensen, P. H. B., & Kim, S. (2018) · Oncogene · doi:10.1038/s41388-017-0102-2 · Cited by 14
“enhancing antitumor immune responses [38].”
Bao, Y., Hu, Q., Wang, X., Feng, X., He, Y. G., Guo, Y., & Fu, D. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110377 · Cited by 14
MicroRNAs as modulators of T cell functions in cancer
Emming, S., Chirichella, M., & Monticelli, S. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.05.019 · Cited by 14
How patients with an intact immune system develop head and neck cancer
Greene, S., Patel, P., & Allen, C. T. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.03.010 · Cited by 14
Mathematical modelling of tumour-induced angiogenesis
Addison-Smith, E. A. (2010) · Cited by 15
ANGPTL2 ‐mediated epigenetic repression of MHC‐I in tumor cells accelerates tumor immune evasion
Kadomatsu, T., Hara, C., Kurahashi, R., Horiguchi, H., Morinaga, J., Miyata, K., Kurano, S., Kanemaru, H., Fukushima, S., Araki, K., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13490 · Cited by 13
Shannon, A. H., Manne, A., Diaz, D. A., & Pawlik, T. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1193762 · Cited by 13
Current Status of Immunotherapy Treatments for Pancreatic Cancer
Jiménez‐Luna, C., Prados, J. C., Ortíz, R., Melguizo, C., Torres, C., & Caba, O. (2016) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000623 · Cited by 15
Sun, K., Zhang, X., Lao, M., He, L., Wang, S., Yang, H., Xu, J. M., Tang, J., Hong, Z., Song, J., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.07.021 · Cited by 13
Zhao, Y., Zhang, Y., Lu, W., Sun, R., Guo, R., Cao, X., Liu, X., Lyu, C., & Zhao, M. (2023) · BMC Medical Genomics · doi:10.1186/s12920-023-01735-0 · Cited by 13
“IFN stimulates immune surveillance and cancer immune editing capacity are important parts of its anti-tumor effect [8].”
BackgroundIn vivoprofiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma
Urosevic‐Maiwald, M., Barysch, M. J., Cheng, P. F., Karpova, M. B., Steinert, H. C., Okoniewski, M. J., & Dummer, R. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.988458 · Cited by 14
“The importance of antitumor immunity in host control of tumor development is one of the cornerstones of the “cancer immunoediting” theory.37 Accordingly, the immune system is not only capable of destroying tumor cells through the activation of adaptive and innate immune IFN-dependent pathways, it can also facilitate t…”
BackgroundWang, S., Patsis, C., & Koromilas, A. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420671112 · Cited by 15
“One mechanism depends on the induction of antitumor immune responses (6) and the other on the suppression of oncogenic signaling in a cell-autonomous (tumor cell-specific) manner (7–11).”
BackgroundIsolation and activity of the promoters for STAT1 and 2 in Atlantic salmon Salmo salar
Collins, C., Ganne, G., & Collet, B. (2014) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2014.07.025 · Cited by 13
Griffith, T. S., & James, B. R. (2014) · Research and Reports in Biochemistry · doi:10.2147/rrbc.s59123 · Cited by 14
Gaire, B., Padmanabhan, S., Zou, Y., Uddin, M. M., Reddy, S. U., & Vancurova, I. (2023) · FEBS Open Bio · doi:10.1002/2211-5463.13624 · Cited by 10
Metadata
- Authors
- Dunn, G. P., Koebel, C. M., & Schreiber, R. D.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Schreiber, Robert D.
- Venue
- Nature Reviews Immunology
- Published
- 2006-11
- Volume
- 6
- Issue
- 11
- Pages
- 836-848
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2052313621
- Cited by
- 1,617
- References
- 119
- Citations by year
- 2026: 33 · 2025: 51 · 2024: 87 · 2023: 104 · 2022: 84 · 2021: 94 · 2020: 93 · 2019: 73 · 2018: 85 · 2017: 74 · 2016: 93 · 2015: 100 · 2014: 100 · 2013: 79 · 2012: 76
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- interferon, type I interferon, interferon-gamma, cancer immunoediting, tumor surveillance, antitumor immunity, tumor-immune interactions, interferon-alpha, interferon-beta, cancer immunotherapy
- MeSH terms
- Animals, Humans, Immunity, Immunotherapy, Interferons, Neoplasms, Monitoring, Immunologic, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.